瑞士制药公司Idorsia 出售其药品专利权, 获得35M, 计划裁员。 Swiss drug firm Idorsia sells rights to its drug aprocitentan, gets $35M, plans job cuts.

瑞士制药公司Idorsia正在进行排他性谈判,以出售其药物专利权的全球权利,收取3 500万美元的排他性费用,将其金融跑道延长到2025年。 Swiss pharmaceutical company Idorsia is in exclusive negotiations to sell global rights to its drug aprocitentan, receiving a $35 million exclusivity fee, which extends its financial runway to 2025. 这笔交易还可能包括额外付款。 The deal may also include additional payments. Idorsia计划精简业务,可能削减全球约270个就业机会,并重组其债务结构。 Idorsia plans to streamline operations, potentially cutting about 270 jobs globally, and restructure its debt.